By investigating the antitumor performance in vivo, we found that the NLG919/IR780‐micelle‐mediated PTT and immunotherapy efficiently inhibited the primary tumor, suppressed the growth of secondary tumor, and increased the infiltrated T cells in tumor tissue, favoring the differentiation of T cells to CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.